118 related articles for article (PubMed ID: 36778274)
1. Clinical outcomes for pleomorphic xanthoastrocytoma patients: an institutional experience.
Sullivan J; Chandler J; Lesniak M; Tate M; Sonabend A; Kalapurakal J; Horbinski C; Lukas R; Kumthekar P; Sachdev S
Res Sq; 2023 Feb; ():. PubMed ID: 36778274
[TBL] [Abstract][Full Text] [Related]
2. Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma.
Tonse R; Gupta T; Epari S; Shastri JG; Gurav M; Bano N; Jalali R
J Neurooncol; 2018 Jan; 136(2):343-350. PubMed ID: 29147864
[TBL] [Abstract][Full Text] [Related]
3. BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study.
Ma C; Feng R; Chen H; Hameed NUF; Aibaidula A; Song Y; Wu J
World Neurosurg; 2018 Dec; 120():e1225-e1233. PubMed ID: 30240866
[TBL] [Abstract][Full Text] [Related]
4. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
[TBL] [Abstract][Full Text] [Related]
5. Impact of Grade on Survival in Pleomorphic Xanthoastrocytoma and Low Prevalence of BRAF V600E Mutation.
Gandham EJ; Goyal-Honavar A; Beno D; Pai R; Balakrishan R; Jasper A; Gowri M; Moorthy RK; Chacko AG; Chacko G
World Neurosurg; 2022 Aug; 164():e922-e928. PubMed ID: 35618235
[TBL] [Abstract][Full Text] [Related]
6. Biology and grading of pleomorphic xanthoastrocytoma-what have we learned about it?
Vaubel R; Zschernack V; Tran QT; Jenkins S; Caron A; Milosevic D; Smadbeck J; Vasmatzis G; Kandels D; Gnekow A; Kramm C; Jenkins R; Kipp BR; Rodriguez FJ; Orr BA; Pietsch T; Giannini C
Brain Pathol; 2021 Jan; 31(1):20-32. PubMed ID: 32619305
[TBL] [Abstract][Full Text] [Related]
7. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.
Tabouret E; Bequet C; Denicolaï E; Barrié M; Nanni I; Metellus P; Dufour H; Chinot O; Figarella-Branger D
Eur J Surg Oncol; 2015 Dec; 41(12):1685-90. PubMed ID: 26454767
[TBL] [Abstract][Full Text] [Related]
8. Predictors of outcome in pleomorphic xanthoastrocytoma.
Dono A; Lopez-Rivera V; Chandra A; Lewis CT; Abdelkhaleq R; Sheth SA; Ballester LY; Esquenazi Y
Neurooncol Pract; 2021 Apr; 8(2):222-229. PubMed ID: 33898055
[TBL] [Abstract][Full Text] [Related]
9. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.
Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G
Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588
[TBL] [Abstract][Full Text] [Related]
10. Pleomorphic xanthoastrocytomas: institutional experience of 18 patients.
Oh T; Kaur G; Madden M; Bloch O; Parsa AT
J Clin Neurosci; 2014 Oct; 21(10):1767-72. PubMed ID: 24950906
[TBL] [Abstract][Full Text] [Related]
11. Pleomorphic xanthoastrocytoma: long-term results of surgical treatment and analysis of prognostic factors.
Gallo P; Cecchi PC; Locatelli F; Rizzo P; Ghimenton C; Gerosa M; Pinna G
Br J Neurosurg; 2013 Dec; 27(6):759-64. PubMed ID: 23514331
[TBL] [Abstract][Full Text] [Related]
12. Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.
Ida CM; Rodriguez FJ; Burger PC; Caron AA; Jenkins SM; Spears GM; Aranguren DL; Lachance DH; Giannini C
Brain Pathol; 2015 Sep; 25(5):575-86. PubMed ID: 25318587
[TBL] [Abstract][Full Text] [Related]
13. Pleomorphic Xanthoastrocytoma: a single institution retrospective analysis and a review of the literature.
Detti B; Scoccianti S; Maragna V; Lucidi S; Ganovelli M; Teriaca MA; Caini S; Desideri I; Agresti B; Greto D; Buccoliero AM; Puppa AD; Sardi I; Livi L
Radiol Med; 2022 Oct; 127(10):1134-1141. PubMed ID: 35951279
[TBL] [Abstract][Full Text] [Related]
14. Clinical features and surgical outcomes of high grade pleomorphic xanthoastrocytomas: a single-center experience with a systematic review.
Zuo P; Li T; Sun T; Wu W; Wang Y; Zhang M; Wu Z; Zhang J; Zhang L
Front Oncol; 2023; 13():1193611. PubMed ID: 37448517
[TBL] [Abstract][Full Text] [Related]
15. Peritumoral Edema Affects the Prognosis in Adult Pleomorphic Xanthoastrocytoma: Retrospective Analysis of 25 Patients.
Byun J; Hong SH; Kim YH; Kim JH; Kim CJ
World Neurosurg; 2018 Jun; 114():e457-e467. PubMed ID: 29545226
[TBL] [Abstract][Full Text] [Related]
16. Grade II Pleomorphic Xanthoastrocytoma; a meta-analysis of data from previously reported 167 cases.
Mallick S; Benson R; Melgandi W; Giridhar P; Rath GK
J Clin Neurosci; 2018 Aug; 54():57-62. PubMed ID: 29803334
[TBL] [Abstract][Full Text] [Related]
17. Clinical, Morphological, and Molecular Study on Grade 2 and 3 Pleomorphic Xanthoastrocytoma.
Zhang H; Ma XJ; Xiang XP; Wang QY; Tang JL; Yu XY; Xu JH
Curr Oncol; 2023 Feb; 30(2):2405-2416. PubMed ID: 36826144
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of spinal ependymomas: an institutional experience of more than 60 cases.
Savoor R; Sita TL; Dahdaleh NS; Helenowski I; Kalapurakal JA; Marymont MH; Lukas R; Kruser TJ; Smith ZA; Koski T; Ganju A; Sachdev S
J Neurooncol; 2021 Jan; 151(2):241-247. PubMed ID: 33179213
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
[TBL] [Abstract][Full Text] [Related]
20. Patterns of care and outcomes of patients with pleomorphic xanthoastrocytoma: a SEER analysis.
Perkins SM; Mitra N; Fei W; Shinohara ET
J Neurooncol; 2012 Oct; 110(1):99-104. PubMed ID: 22843450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
